Incyte and Biogen Enter Into Genomic Partnership
PALO ALTO, Calif., Jan. 13 /PRNewswire/ -- Incyte Pharmaceuticals, Inc. (Nasdaq: INCY - news), a leading provider of genomic information, announced today that Biogen will gain access to Incyte's LifeSeq© Gold assembled database and LifeTools(TM) enterprise-wide data management software. Incyte could receive future milestone payments and royalties on sales of products developed with Incyte technology and database information. Financial terms were not disclosed.
LifeSeq Gold is a powerful platform for drug discovery, providing the best view of genes, their function, and their role in disease development. LifeSeq Gold currently contains nearly 5 million human gene sequences integrating millions of Incyte novel gene sequences with public data from the Human Genome Project, providing researchers at Biogen with a comprehensive view of the genome. There are approximately 130,000 genes contained in LifeSeq Gold, representing an estimated 90% of the expressed genes in the human genome. As a LifeSeq Gold subscriber, Biogen will also have access to
nearly 200,000 sequence verified clone reagents, or copies of genes, for use in further drug development.
LifeTools is a scalable data management system, allowing researchers at Biogen to process, store, analyze, and manage the explosion of genomic information. This enterprise-wide software will enable scientists at Biogen to easily track research projects and share data with team members directly from their desktops. LifeTools also provides scientists with extensive project management capabilities to manage animal, plant, microbial, and other biological research data.
To date, Incyte has filed patent applications covering an estimated 50,000 individual human genes. The Company has been issued over 350 U.S. patents covering full-length genes, bringing its total number of issued and allowed full-length gene patents to over 480.
"The addition of Biogen as a genomic collaborator is part of our strategy of broadening our customer base," said Roy A. Whitfield, Chief Executive Officer of Incyte. "We are pleased to aid Biogen's efforts in developing new drug compounds by supplying them with important genomic information and intellectual property through our LifeSeq Gold database."
Incyte Pharmaceuticals, Inc. is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases, genomic data management software, microarray-based gene expression services, related reagents and services. These products and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at www.incyte.com.
Except for the historical information contained herein, the matters set forth in this press release, are forward-looking statements within the meaning of the "safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 1999. Incyte disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Incyte Pharmaceuticals, Inc. |
